Halozyme lifts 2026 revenue outlook after strong Q3 and wins European patent case
Halozyme Therapeutics reported third‑quarter 2026 revenue of $493 million, a 39% year‑over‑year increase, and royalty revenue of $341 million, up 44%. The company raised its full‑year 2026 revenue guidance to $1.86‑$1.925 billion and non‑GAAP diluted EPS guidance to $8.75‑$9.05. In October, a Dutch patent court barred Merck from launching its subcutaneous Keytruda product in eight European countries, citing infringement of Halozyme’s patent.
Why it matters
The higher guidance suggests stronger cash flow and may support continued share repurchases, as noted by the CFO. The injunction limits a competitor’s product launch in key markets, potentially protecting Halozyme’s royalty stream.
Key facts
- 1Q3 2026 total revenue was $493 million, a 39% increase versus the prior year. prnewswire.com
- 2Royalty revenue for the quarter reached $341 million, up 44% YoY. prnewswire.com
- 3Full‑year 2026 revenue guidance was raised to a range of $1.860‑$1.925 billion. prnewswire.com
- 4Non‑GAAP diluted EPS guidance for 2026 was increased to $8.75‑$9.05 per share. prnewswire.com
- 5A Dutch specialized patent court issued an injunction preventing Merck from manufacturing, offering, or marketing its subcutaneous Keytruda product in Belgium, Denmark, France, Ireland, Italy, Sweden, Switzerland and the Netherlands. prnewswire.com
- 6During Q3, Halozyme repurchased about 0.8 million shares for $67.2 million, contributing to $400 million of share buybacks in 2026. sec.gov
Summary written by AlphAI AI Desk from 10 of 10 sources. Not investment advice. Figures are as stated by the linked sources.